W. R. Grace & Co. (GRA) Stock Analysis
DELISTED 2021
What happened to W. R. Grace & Co. (GRA) stock?
W. R. Grace & Co. (GRA) no longer trades on public markets. It was delisted in September 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
W. R. Grace & Co. (GRA). GRA operates within the healthcare sector, focusing on early cancer detection. The company leverages advanced technologies to improve patient outcomes through proactive screening. Sector: Healthcare.
Last analyzed: Mar 18, 2026W. R. Grace & Co. (GRA) Healthcare & Pipeline Overview
GRA is a healthcare company specializing in early cancer detection through innovative technologies. With a focus on improving patient outcomes via proactive screening, GRA aims to transform cancer care by enabling earlier interventions and personalized treatment strategies, operating within the rapidly evolving healthcare technology sector.
What Is the Investment Thesis for GRA?
GRA presents a compelling investment thesis centered on its pioneering role in early cancer detection. The company's multi-cancer early detection (MCED) test has the potential to transform cancer care by enabling earlier interventions and personalized treatment strategies. Key value drivers include the growing demand for proactive healthcare solutions, the increasing prevalence of cancer, and the potential for MCED testing to improve patient outcomes and reduce healthcare costs. Upcoming catalysts include continued clinical validation of GRA's MCED test, expansion of its commercial reach, and favorable regulatory developments. However, potential risks include competition from other early cancer detection technologies, challenges in securing reimbursement coverage, and uncertainties surrounding the long-term clinical utility of MCED testing. Investors should closely monitor GRA's progress in addressing these risks and capitalizing on its growth opportunities.
Based on FMP financials and quantitative analysis
GRA Key Highlights
GRA focuses on early cancer detection, a rapidly growing area within healthcare.
- The company's multi-cancer early detection (MCED) test has the potential to transform cancer care.
- GRA collaborates with leading healthcare institutions and research organizations.
- GRA aims to shift the paradigm of cancer care from reactive treatment to proactive prevention.
- GRA's MCED test analyzes circulating tumor DNA (ctDNA) and other biomarkers to identify cancer signals.
Who Are GRA's Competitors?
GRA is benchmarked below against 5 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| HEAL Global X - HealthTech ETF | $30.15 | +0.72% | $33.0M | 44 |
| DOCRF CloudMD Software & Services Inc. | $0.02 | -19.29% | $6.25M | 38 |
| COTV Cotiviti Holdings, Inc. | $44.74 | -0.04% | 52 | |
| HMSY HMSY | $36.98 | +0.00% | 48 | |
| PAFO Pacifico Acquisition Corp. | $4.20 | -47.04% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRA's Key Strengths?
Pioneering technology in early cancer detection
- Strong clinical data supporting test performance
- Established partnerships with leading healthcare institutions
- Experienced management team
What Are GRA's Weaknesses?
Limited commercial track record
- Dependence on regulatory approvals and reimbursement
- Competition from other early cancer detection technologies
- High cost of test development and commercialization
What Could Drive GRA Stock Higher?
Publication of additional clinical data supporting the performance of GRA's MCED test.
- Expansion of GRA's commercial reach through partnerships with healthcare providers and employers.
- Regulatory approvals and reimbursement coverage for GRA's MCED test in key markets.
What Are the Key Risks for GRA?
Competition from other early cancer detection technologies.
- Challenges in securing reimbursement coverage for GRA's MCED test.
- Uncertainties surrounding the long-term clinical utility of MCED testing.
- Dependence on regulatory approvals and reimbursement decisions.
What Are the Growth Opportunities for GRA?
- Expansion of Commercial Reach: GRA has the opportunity to expand its commercial reach by targeting new markets and customer segments. This includes partnering with healthcare providers, employers, and payers to offer its MCED test to a broader population. Timeline: Ongoing.
- Continued Clinical Validation: GRA can further strengthen its competitive position by continuing to generate robust clinical evidence supporting the performance and utility of its MCED test. This includes conducting large-scale clinical trials to demonstrate the test's ability to detect cancer at earlier stages and improve patient outcomes. Positive clinical data can drive adoption of GRA's test by healthcare providers and payers. Timeline: Ongoing.
- Development of New Applications: GRA has the potential to develop new applications for its technology beyond early cancer detection. This includes using its platform to monitor cancer recurrence, personalize treatment decisions, and develop new cancer therapies. By expanding its product portfolio, GRA can diversify its revenue streams and create new growth opportunities. Timeline: 3-5 years.
- Strategic Partnerships and Acquisitions: GRA can accelerate its growth by forming strategic partnerships and acquisitions. This includes collaborating with other healthcare companies, research institutions, and technology providers to expand its capabilities and reach. Acquisitions can provide GRA with access to new technologies, markets, and talent. Timeline: Ongoing.
- Regulatory Approvals and Reimbursement: GRA's success depends on securing regulatory approvals and reimbursement coverage for its MCED test. This includes working with regulatory agencies to obtain clearance or approval for its test and negotiating reimbursement agreements with payers. Favorable regulatory and reimbursement decisions can drive adoption of GRA's test and increase its revenue potential. Timeline: Ongoing.
What Threats Does GRA Face?
- Competition from established diagnostic companies
- Unfavorable regulatory or reimbursement decisions
- Technological advancements by competitors
- Economic downturn affecting healthcare spending
What Are GRA's Competitive Advantages?
- Proprietary Technology: GRA's MCED test is based on proprietary technology that is difficult for competitors to replicate.
- Clinical Data: GRA has generated a significant amount of clinical data supporting the performance and utility of its test.
- Partnerships: GRA has established partnerships with leading healthcare institutions and research organizations.
- Regulatory Approvals: GRA has secured regulatory approvals for its MCED test in certain markets.
What Does GRA Do?
GRA is dedicated to pioneering advancements in early cancer detection. The company focuses on developing and commercializing innovative technologies designed to identify cancer signals at the earliest stages, even before symptoms appear. By leveraging cutting-edge science and technology, GRA aims to shift the paradigm of cancer care from reactive treatment to proactive prevention and early intervention. GRA's primary offering is a multi-cancer early detection (MCED) test designed to detect numerous cancer types from a single blood draw. This test analyzes circulating tumor DNA (ctDNA) and other biomarkers to identify cancer signals, providing healthcare professionals with actionable insights to guide further diagnostic evaluation and treatment planning. GRA's commitment extends beyond technology development to include clinical validation and real-world implementation of its MCED test. The company collaborates with leading healthcare institutions and research organizations to generate robust clinical evidence supporting the performance and utility of its test. GRA also works to educate healthcare providers and patients about the benefits of early cancer detection and the role of MCED testing in improving cancer outcomes. By focusing on early detection, GRA strives to reduce the burden of cancer on individuals, families, and healthcare systems, ultimately contributing to a future where cancer is detected and treated at its most curable stages.
What Products and Services Does GRA Offer?
- Develop and commercialize innovative technologies for early cancer detection.
- Offer a multi-cancer early detection (MCED) test that detects numerous cancer types from a single blood draw.
- Analyze circulating tumor DNA (ctDNA) and other biomarkers to identify cancer signals.
- Provide healthcare professionals with actionable insights to guide further diagnostic evaluation and treatment planning.
- Collaborate with leading healthcare institutions and research organizations to generate clinical evidence.
- Educate healthcare providers and patients about the benefits of early cancer detection.
How Does GRA Make Money?
- GRA generates revenue primarily through the sale of its multi-cancer early detection (MCED) test.
- The company partners with healthcare providers, employers, and payers to offer its test to patients.
- GRA may also generate revenue through research collaborations and licensing agreements.
What Industry Does GRA Operate In?
GRA operates within the healthcare technology industry, specifically in the rapidly evolving field of early cancer detection. The market for early cancer detection technologies is experiencing significant growth, driven by the increasing prevalence of cancer, the growing demand for proactive healthcare solutions, and the potential for early detection to improve patient outcomes and reduce healthcare costs. GRA competes with other companies developing early cancer detection technologies, including liquid biopsy companies and traditional screening methods. The company's success depends on its ability to differentiate its MCED test through superior performance, clinical validation, and commercial execution.
Who Are GRA's Key Customers?
- Healthcare providers (e.g., physicians, hospitals, cancer centers)
- Employers (offering the test as a benefit to employees)
- Payers (e.g., insurance companies, government healthcare programs)
- Patients (individuals seeking early cancer detection)
GRA Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in W. R. Grace's future performance, indicating that leadership believes in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting the company’s strong position in specialty chemicals and materials.
- Market perception has been bolstered by recent partnerships that enhance product offerings and expand market reach, showcasing innovation.
- The company's focus on sustainability aligns with industry trends, appealing to environmentally conscious investors and consumers.
Bear Case
- Concerns over supply chain disruptions have affected sentiment, raising questions about the company's ability to meet demand effectively.
- Recent bearish commentary from analysts suggests caution regarding the competitive landscape, which could pressure margins and growth.
- Market volatility and economic uncertainty are causing some investors to reassess their positions in industrial sectors, including chemicals.
- Negative sentiment from social trading platforms indicates a growing skepticism about the company's ability to sustain recent operational improvements.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GRA Latest News
No recent news available for GRA.
Classification
Industry Healthcare TechnologyGRA Healthcare Stock FAQ
What happened to W. R. Grace & Co. (GRA) stock?
W. R. Grace & Co. (GRA) no longer trades on public markets. It was delisted in September 2021. The figures below are historical and are not a current quote.
Can I still buy GRA shares?
No. GRA stopped trading on public markets in September 2021, so the shares are not available through a broker. Anything you see quoted for GRA elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before GRA stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to W. R. Grace & Co.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does GRA do?
GRA is a healthcare company focused on early cancer detection. They have developed a multi-cancer early detection (MCED) test that analyzes circulating tumor DNA (ctDNA) and other biomarkers from a single blood draw to detect cancer signals. This technology aims to enable earlier interventions and personalized treatment strategies, potentially improving patient outcomes and reducing healthcare costs.
What do analysts say about GRA stock?
Analyst coverage of GRA focuses on the potential of its MCED test to transform cancer care. Key valuation metrics include revenue growth, market penetration, and reimbursement coverage. Growth considerations center on the company's ability to secure regulatory approvals, expand its commercial reach, and generate robust clinical evidence supporting the test's performance.
What are the main risks for GRA?
The main risks for GRA include competition from other early cancer detection technologies, challenges in securing reimbursement coverage for its MCED test, and uncertainties surrounding the long-term clinical utility of MCED testing. The company also faces regulatory risks and depends on securing approvals for its test. Additionally, the high cost of test development and commercialization poses a financial risk.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide further insights.